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rare (MAF: 0.8%) missense (A1690V) variant in CUBN (rs141640975, β =0.27, p=1.3 × 10 -11 ) associated with albuminuria as a continuous measure in the combined European meta-analyses.
Presence of each rare allele of the variant was associated with a 6.4% increase in albuminuria. The rare CUBN variant had 3 times stronger effect in individuals with diabetes compared to those without (p interaction : 5.4 × 10 -4 , β DM : 0.69, β nonDM : 0.20) in the discovery meta-analyses. Geneaggregate tests based on rare and common variants identify three additional genes associated with albuminuria (HES1, CDC73, and GRM5) after multiple testing correction (p _bonferroni <2.7 × 10 -6 ).
The current study identifies a rare coding variant in the CUBN locus and other potential genes associated with albuminuria in individuals with and without diabetes. These genes have been implicated in renal and cardiovascular dysfunction. These findings provide new insights into the genetic architecture of albuminuria and highlight novel target genes and pathways for prevention of diabetes-related kidney disease.
Introduction
Albuminuria is a manifestation of chronic kidney disease (CKD), a major health burden worldwide with a current prevalence of 14.8% in the United States 1 . In individuals with CKD, changes in albuminuria are strongly associated with the risk of end-stage renal disease and death 2 . Albuminuria has also been associated with increased risk of cardiovascular disease and mortality among individuals with and without diabetes [3] [4] [5] .
Family-studies suggest that genetic factors explain 16% to 49% of albuminuria 6 . While several genome wide association studies (GWAS) of albuminuria have been performed to date, most have focused on identifying common genetic variants (minor allele frequency (MAF) ≥ 5%) for albuminuria [6] [7] [8] . In a recent study, we identified rare coding variants for kidney function (estimated glomerular filteration rate, eGFR) and development using exome-wide association analyses 9 . Here, we use a similar approach to identify rare (MAF <1%) or low frequency (MAF 1-5%) coding variants for albuminuria in 33,985 individuals of European ancestry with (n=15,872) and without (n=18,111) diabetes.
Materials and Methods

Study populations
The present study comprises a two-stage design: discovery and replication. The discovery set includes five cohorts from Denmark (Inter99, Health-2006, Health-2008, Vejle Biobank, and  Addition-DK) with a total of 13,226 participants (3,896 with and 9,330 without diabetes), described previously 10, 11 (Supp. Text 1.1).
The replication set includes multiple studies of European (EUR) descent (n EUR : 20,759; 11,976 with and 8,783 without diabetes) including the IMI-SUMMIT consortia (Europe-UK based consortia on diabetes cases) 12 , and Greenlandic (GL) Inuit populations (n GL : 2,605) which are all described in P a g e 5 detail in Supp. Text 1.2. The overall study design involving the single SNP association testing and Gene based aggregate testing has been presented in form of process flow diagrams ( Figure 1A and   1B ).
The present study was conducted in accordance with the Helsinki declaration and all the participating studies were approved by their respective Data Protection Boards and by the regional scientific ethics committees. All participants signed a written consent.
Phenotype measurements
Albuminuria was diagnosed from a 24-hour urine collection (mg/24 hours), also called the urinary albumin excretion rate (AER) or, from spot urine samples measuring urinary albumin and creatinine concentrations and calculating their ratio (ACR in mg/g). The methods used to measure AER/ACR by participating cohorts have been described in the Supp. table S1.1 with phenotype measures summary in Table 1 .
Genotyping and SNP quality control
Genotyping of the discovery phase studies was performed on the Illumina HumanExome BeadChip 12V.1.0 containing 2,44,883 single nucleotide polymorphisms (SNPs) plus additional ~17,000 custom-typed SNPs from the Danish Exome Sequencing Project as described previously 13 . The total number of SNPs was 263,894 of which most were exome based (non-synonymous/coding) gene variants (~90%). Thus, we refer to the present association study as an exome-wide association study (Ex-WAS).
Genotyping methods and quality control (QC) based inclusions and exclusions in the discovery and replication (20,759 EUR and 2,605 GL) cohorts have been described in Supp. table S1.2.
Albeit a total of 54,606 SNPs remained for a total of 13,226 individuals with complete phenotype and genotype data in the discovery set.
Statistical analyses
Discovery Phase meta Ex-WAS
The discovery phase Ex-WAS for albuminuria was first performed in each of the five participating studies individually using additive linear regression model adjusting for gender, age, and population sub-structure (first ten principal components), and systolic blood pressure (SBP) wherever available. Albuminuria measurements were natural log transformed to correct for non-normalised data.
The study-specific results were meta-analysed (meta Ex-WAS) using inverse variance-weighted fixed effects meta-analyses where weights are proportional to the squared standard errors of the effect estimates. Genomic inflation factor (λ) was at acceptable levels both in the individual study Ex-WAS (λ inter99 = 1.01, λ health2006 = 1.0, λ health2008 = 1.0, λ vejle = 0.99, λ addition_dk = 1.01) and in the combined discovery meta Ex-WAS (λ discovery =1.0). A chi-square test for heterogeneity was implemented to estimate the heterogeneity in effect sizes across the participating studies. The METAL software (http://csg.sph.umich.edu/abecasis/metal/) was used for meta-analyses and the R meta package (https://github.com/guido-s/meta) for constructing meta forrest plots (discovery set).
Ancestry specific linkage disequilibrium (LD) between variants was extracted using the NIH based LDlink database (https://analysistools.nci.nih.gov/LDlink/) or through the SNAP (SNP Annotation and Proxy Search) (http://archive.broadinstitute.org/mpg/snap/index.php) database.
Replication Phase meta analyses
SNPs with p < 5.0 × 10 -5 in the discovery meta-analyses were tested for replication in European (n EUR : 20, 759) and Greenlandic (n GL : 2,605) study cohorts independently using the linear regression models (adjusting for study specific covariates). SNPs with imputation quality r 2 <0.3 were not used for replication. Following this an inverse variance or p value based fixed effects meta-analyses was P a g e 8 less than 2 contributing variants were filtered out. A Bonferroni-based correction was applied on 18, 026 gene sets tested (p adjusted <2.7 × 10 -6 ).
Phenome Scanning: SNP-trait associations from publicly available data (GWAS, eQTL based gene expression, and SNP-Metabolite associations)
The Pheno Scanner database (http://www.phenoscanner.medschl.cam.ac.uk/phenoscanner) comprising publicly available results for SNP-trait associations (GWAS, eQTL and metabolomics data) for the European ancestry 15 was used to mine known SNP-Trait associations of the current SNP findings.
SNP functionality prediction: SIFT
We used the SIFT (Sorting Intolerant from Tolerant) database to check whether any top coding variant was associated with functional by nature (http://sift.bii.a-star.edu.sg/).
RESULTS
SNP-Albuminuria Association Analyses
Discovery Phase
In stage 1 discovery phase meta-analyses comprising five Danish studies (n total : 13,226), three independent SNPs reached p discovery < 5.0 × 10 -5 . This included two rare variants (MAF<0.01) in CUBN and LMX1B and a common variant in KCNK5. The quantile-quantile (QQ) and manhattan plot (stage 1) can be found in the supplementary material (Supp. figures S1a and S1b) along with the locus zoom plots for the 3 top SNP signals (Supp. figures S2a, S2b, and S2c).
Top signal in CUBN (cubilin) gene rs141640975 is a rare (MAF: 0.0083) missense (A1690V) SNP with the A allele associated with increased albuminuria (β: 0.25; p discovery : 1.2 × 10 -5 , Pheno Scanner based results on published literature suggests that the CUBN rare SNP is associated with creatinine levels in a blood based metabolomics study (p: 0.014).
The suggestive KCNK5 SNP is a known CAD GWAS significant locus. Additional traits associated with rs10947789 C allele include urinary albumin creatinine ratio (UACR, CKD-gen consortia, β : 0.025, p: 5.6 × 10 -4 ), myocardial infarction (CARDIoGRAMplusC4D consortia, β : -0.059, p: 1.4 × 10 -6 ), visual refractive error (β: 0.11, p: 0.003), and birthweight (Early Growth Genetics (EGG) Consortium, β : 0.025, p<0.007).
eQTL data suggests rs10947789 C allele specific gene expression associations within adrenal gland (β: 0.51, p: 2.5 × 10 -5 ), subcutaneous adipose tissue (β: 0.34, p: 7.2 × 10 -5 ), lymphoblastoid cell line (β: 0.03, p: 0.0019) and tibial nerve (β: 0.15, p: 0.002).
Detailed SNP-trait associations (GWAS, eQTL and serum metabolome) have been documented in Supp. tables S1.5a-c.
SNP Functionality Prediction: SIFT
We used the SIFT (Sorting Intolerant from Tolerant) database (web version) to check whether any top coding variant was associated with functional by nature (http://sift.bii.a-star.edu.sg/). CUBN missense rare SNP rs141640975 was described as functionally deleterious with a SIFT median value of 3.44 (Supp. Table S1.6).
Discussion
In the discovery meta Ex-WAS of 13,226 Europeans (5 cohorts) followed by replication in 20,759
Europeans (12 cohorts) and 2,605 Greenlandic Inuit (2 cohorts), we identify one novel CUBN variant associated with albuminuria levels in the combined European meta-analyses.
Albeit CUBN is a known locus for albuminuria, the identified rare missense variant shows independent effects (with respect to the known CUBN common SNP), stronger within the diabetes versus non-diabetes group (p interaction : 5.4 × 10 -4 ). This rare variant explains upto 6.4% variance per P a g e 1 2
rare allele (in a model adjusted for age and gender) of albuminuria levels (natural log transformed).
Also the gene-based tests identify three additional genes (HES1, CDC73, and GRM5) that associate with albuminuria (p Bonferroni <2.7 × 10 -6 ) in a meta-analyses comprising six Scandinavian cohorts.
Another SNP passing discovery stage in the KCNK5 gene replicates (p = 0.03) and seems interesting, but does not reach the genome wide threshold in the combined European-Greenlandic (EUR-GL) meta-analyses (p: 9.1 × 10 -6 , ups indicate rs10947789 associated strongly with KCNK5 expression in the adrenal gland (p: 2.5 × 10 -5 ) and subcutaneous adipose tissue (p: 7.2 × 10 -5 ), while nominally in the nervous system tissues (p<0.01), suggesting a functional role in the kidneys and adipose tissue (Supp. table S1.5b).
KCNK5 is also associated with Balkan endemic nephropathy 33 . Overall, the KCNK5 locus may play an important role in the cardio-renal axis through modification in albuminuria levels.
We performed gene-based tests in order to capture the aggregate effect of gene-specific rare and low frequency variants on albuminuria. Three new genes that were found associated with albuminuria where HES1, CDC73 and GRM5.
HES1 gene is a transcription factor that is ubiquitously expressed in most organs, also including the kidneys, and has been documented to be involved in Notch signaling pathways that play a role in renal fibrosis 34 , glomerulosclerosis 35 , and other forms of kidney disease 34, 36 . The CDC73 gene is a tumor suppressor gene whose mutations have been associated to hyperparathyroidism-jaw syndrome and familial hyperparathyroidism 37 . Albuminuria is associated with hyperparathyroidism which is a complication of CKD 38 , and the present findings may thus suggest a plausible link between the two.
GRM5 encodes glutamate metabotropic receptor 5 which is a G protein coupled receptor involved in second messenger signaling activated by phosphatidylinositol-calcium. Variants in the metabotropic glutamate receptor group I pathway, including GRM1 and GRM5, were strongly enriched in the pathway analysis of a previous GWAS on albuminuria in individuals with type 1 diabetes from the FinnDiane study 8 , without any overlapping individuals with the current gene aggregate meta-analysis. GRM5 was recently documented to be expressed in podocytes, also associating with podocyte apoptosis in animals 39 , and reported pharmacological effects in humans 40 .
In summary, we identify a novel rare coding CUBN variant implicated in elevated albuminuria levels especially in individuals with diabetes. Further we also identify additional novel P a g e 1 5
genes associated with albuminuria through an alternate gene-aggregate approach among Europeans.
Our findings provide fresh insights into the genetic architecture of albuminuria and highlight new targets, genes and pathways for the prevention and treatment of diabetic kidney disease. W  i  c  h  m  a  n  n  ,  H  E  ,  G  r  a  l  l  e  r  t  ,  H  ,  W  a  l  l  a  s  c  h  o  f  s  k  i  ,  H  ,  V  o  l  z  k  e  ,  H  ,  B  r  e  n  n  e  r  ,  H  ,  K  r  a  m  e  r  ,  H  ,  M  a  t  e  o  L  e  a  c  h  ,  I  ,   R  u  d  a  n  ,  I  ,  H  i  l  l  e  g  e  ,  H  L  ,  B  e  c  k  m  a  n  n  ,  J  S  ,  L  a  m  b  e  r  t  ,  J  C  ,  L  u  a  n  ,  J  ,  Z  h  a  o  ,  J  H  ,  C  h  a  l  m  e  r  s  ,  J  ,  C  o  r  e  s  h  ,  J  ,  D  e  n  n  y  ,  J  C  ,   B  u  t  t  e  r  b  a  c  h  ,  K  ,  L  a  u  n  e  r  ,  L  J  ,  F  e  r  r  u  c  c  i  ,  L  ,  K  e  d  e  n  k  o  ,  L  ,  H  a  u  n  ,  M  ,  M  e  t  z  g  e  r  ,  M  ,  W  o  o  d  w  a  r  d  ,  M  ,  H  o  f  f  m  a  n  ,   M  J  ,  N  a  u  c  k  ,  M  ,  W  a  l  d  e  n  b  e  r  g  e  r  ,  M  ,  P  r  u  i  j  m  ,  M  ,  B  o  c  h  u  d  ,  M  ,  R  h  e  i  n  b  e  r  g  e  r  ,  M  ,  V  e  r  w  e  i  j  ,  N  ,  W  a  r  e  h  a  m  ,  N J ,
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Figure 1. Study Design Overview:
A. Exome wide association study (Ex-WAS) on Albuminuria: A multi stage study on Europeans and Greenlanders P a g e 2 6
B. Gene Aggregate Testing: Identifying trait associated genes, based on summary score statistics
